CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024.
- Revenue
- −3.72%
- EPS
- −12.3%
- Free cash flow
- −25.2%
- Total debt
- 0.00%
Quarter to September 2026, against a year earlier
Follow CGON
Alert me
CG Oncology, Inc. (CGON) EV/FCF
As of 6 November 2026, CG Oncology, Inc. (CGON) trades at a EV/FCF of −30.6×. Over the past ten years it has ranged from −34.5× (March 2026) to 0.5× (March 2024); the current reading is higher than 7% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | −18.7× | — |
| FY2024 | −13.5× | — |
| FY2023 | 0.2× | 0.00% |
| FY2022 | 0.2× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | −28.2× | — |
| Jun 2026 | −29.3× | — |
| Mar 2026 | −29.0× | — |
| Dec 2025 | −18.7× | — |
| 9 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| BLTE Belite Bio, Inc. Sponsored ADR compare | −79.2× |
| MANE Veradermics Incorporated compare | −35.5× |
| KOD Kodiak Sciences Inc. compare | −35.4× |
| CGON CG Oncology, Inc. | −26.2× |
| PTCT PTC Therapeutics, Inc. compare | −24.0× |
| MIRM Mirum Pharmaceuticals, Inc. compare | −21.1× |
| SRRK Scholar Rock Holding Corporation compare | −19.0× |
| IMVT Immunovant, Inc. compare | −12.2× |
| LGND Ligand Pharmaceuticals Incorporated compare | 60.7× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on CGON
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement